e-Therapeutics' Impact is rated World Class

RNS Number : 2500A

e-Therapeutics plc

19 December 2014

 

e-Therapeutics plc 
("e-Therapeutics" or the "Company")

e-Therapeutics' Impact is rated World Class and helps its "home" Computing Science Department to Number 1 in UK National Research and Impact Assessment

Oxford and Newcastle, UK, 18 December 2014 - The impact of e-Therapeutics plc (AIM: ETX)  drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise. 

The impact case study on e-Therapeutics was submitted by Newcastle University's Computing Science department, and this rating helped the Department to the number 1 position in the UK for the impact of its research. 

The Research Excellence Framework (REF) is the five-yearly assessment of the quality of research and impact in all departments of all universities in the UK.  The level of impact is an important aspect of the assessment of the quality of research in UK science departments. The REF highlighted the wide-ranging and significant benefits that UK research brings to the economy and society. For more information, please see: www.ref.ac.uk.

Malcolm Young, CEO of e-Therapeutics, and a Visiting Professor at the University, said: 

"We are proud of our association with Newcastle University. We are delighted that the quality of its computing science, and through e-Therapeutics, its beneficial impact for society, has been recognised by achieving the top spot in the REF."

-Ends-

Contacts:

e-Therapeutics plc

Malcolm Young / Steve Medlicott

Tel: [phone]

www.etherapeutics.co.uk 

N+1 Singer

Aubrey Powell/ Jen Boorer

Tel: [phone]

www.n1singer.com

Instinctif Partners

Melanie Toyne Sewell / Emma Barlow

Tel: [phone]

Email: [e-mail]

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

NRAUWVARSRAUAUA